Could a hidden antibody explain liver injury in anorexia?

NCT ID NCT06869590

Recruiting now Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates whether certain autoantibodies (anti-HIF1a) are more common in people with anorexia nervosa who also have liver damage. Researchers will compare 100 anorexia patients (with and without liver issues) to 150 control participants, including healthy individuals and those with liver damage from other causes. The goal is to confirm earlier findings and better understand the role of these antibodies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward a new understanding of why some people with anorexia develop liver problems, potentially leading to better monitoring or future treatments.
What could go wrong: This is an early-stage observational study, not a treatment trial. It only looks for a link, so it may not lead to any direct therapy. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANOREXIA NERVOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anorexia nervosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC CYTOLYSIS

Contacts and locations

Locations

Assistance Publique Hopitaux De Marseille
RECRUITING

Marseille, 13005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.